Table 3.
SPR analysis of antibody binding to CAA Aβ fibrils.
| Generic name | AD009 | AD062 | AD090 | AD021 | ||||
|---|---|---|---|---|---|---|---|---|
| Bound (RU) | Remaining (%) | Bound (RU) | Remaining (%) | Bound (RU) | Remaining (%) | Bound (RU) | Remaining (%) | |
| Aducanumab | 24.1 | 62 | 4.4 | 46 | 36.2 | 59 | 56.8 | 48 |
| Bapineuzumab | 8.4 | 82 | No binding | 18.4 | 79 | 15.6 | 81 | |
| Crenezumab | No binding | No binding | No binding | No binding | ||||
| Donanemab | 3.7 | 43 | No binding | 7.3 | 41 | 6.2 | 27 | |
| Gantenerumab | 23.9 | 34 | 12.9 | 21 | 35.2 | 41 | 51.5 | 29 |
| Lecanemab | 2.4 | 12 | No binding | 4.8 | 7 | 17.7 | 25 | |
| Solanezumab | No binding | No binding | No binding | No binding | ||||
Bound; average amount of antibody bound to CAA fibrils, expressed as response units (RU).
Remaining; average % remaining bound to CAA fibrils after a 20-min dissociation period.